Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies

Abstract Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. However, potentially severe and hard-to-manage side effects, including cytokine release syndrome (CRS), neurotoxicity and macrop...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Simona Manni, Francesca Del Bufalo, Pietro Merli, Domenico Alessandro Silvestris, Marika Guercio, Simona Caruso, Sofia Reddel, Laura Iaffaldano, Michele Pezzella, Stefano Di Cecca, Matilde Sinibaldi, Alessio Ottaviani, Maria Cecilia Quadraccia, Mariasole Aurigemma, Andrea Sarcinelli, Roselia Ciccone, Zeinab Abbaszadeh, Manuela Ceccarelli, Rita De Vito, Maria Chiara Lodi, Maria Giuseppina Cefalo, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli, Concetta Quintarelli
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2023-06-01
Saila:	Nature Communications
Sarrera elektronikoa:	https://doi.org/10.1038/s41467-023-38723-y
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!